Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$5.95 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.90 million
Earnings per share
-0.316
Dividend per share
N/A
Year To Date Return
34.12%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
⏸️ Investing
Pot stocks rocket: Here's what you need to know
⏸️ Investing
Why the Auscann Group Holdings Ltd share price just rocketed 15% higher
⏸️ Investing
ASX pot stock update: What you need to know
⏸️ Investing
Why these 4 ASX shares started the week with a bang
⏸️ Investing
Why the AusCann share price rocketed higher today
⏸️ Investing
The Zelda Therapeutics Ltd share price is down 7%
⏸️ Investing
ASX-listed pot stocks reviewed
⏸️ Investing
Why these 4 ASX shares have climbed higher today
⏸️ Investing
Why the Zelda Therapeutics Ltd share price rocketed 20% higher today
⏸️ Investing
Why these 4 ASX shares are ending the week with a bang
⏸️ Investing
Why the Zelda Therapeutics Ltd share price rocketed 26% today
⏸️ Investing
Why these 4 ASX shares have fallen lower today
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 23 Feb 2026 | $0.52 | $0.00 | 0.00% | 2,196 | $0.52 | $0.52 | $0.52 |
| 20 Feb 2026 | $0.52 | $-0.05 | -8.77% | 3,480 | $0.57 | $0.57 | $0.52 |
| 19 Feb 2026 | $0.57 | $-0.01 | -1.72% | 1,962 | $0.57 | $0.57 | $0.57 |
| 17 Feb 2026 | $0.58 | $0.02 | 3.57% | 1,894 | $0.60 | $0.60 | $0.58 |
| 16 Feb 2026 | $0.56 | $-0.05 | -8.20% | 26,006 | $0.60 | $0.60 | $0.56 |
| 12 Feb 2026 | $0.61 | $0.01 | 1.65% | 15,058 | $0.61 | $0.61 | $0.61 |
| 11 Feb 2026 | $0.61 | $-0.02 | -3.23% | 20,632 | $0.61 | $0.61 | $0.61 |
| 10 Feb 2026 | $0.62 | $-0.01 | -1.60% | 537 | $0.62 | $0.62 | $0.62 |
| 09 Feb 2026 | $0.63 | $0.01 | 1.61% | 6,196 | $0.62 | $0.63 | $0.62 |
| 06 Feb 2026 | $0.62 | $0.00 | 0.00% | 9,016 | $0.62 | $0.62 | $0.61 |
| 05 Feb 2026 | $0.62 | $0.00 | 0.00% | 2,651 | $0.62 | $0.62 | $0.61 |
| 04 Feb 2026 | $0.62 | $-0.03 | -4.62% | 3,185 | $0.62 | $0.62 | $0.62 |
| 03 Feb 2026 | $0.65 | $0.05 | 8.26% | 1,946 | $0.61 | $0.65 | $0.61 |
| 02 Feb 2026 | $0.61 | $-0.05 | -7.69% | 2,922 | $0.61 | $0.61 | $0.61 |
| 30 Jan 2026 | $0.65 | $0.00 | 0.00% | 8,847 | $0.65 | $0.67 | $0.65 |
| 29 Jan 2026 | $0.65 | $-0.03 | -4.41% | 19,854 | $0.68 | $0.71 | $0.65 |
| 28 Jan 2026 | $0.68 | $-0.04 | -5.52% | 36,887 | $0.74 | $0.75 | $0.68 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 04 Dec 2025 | Oludare Odumosu | Issued | 386,847 | $100,000 |
As advised by the company. USD, convertible notes Issue
|
| 04 Dec 2025 | Donna O'Donnell | Issued | 193,423 | $50,000 |
As advised by the company. USD 50,000, 193,423 Convertible Notes Issue
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. He has over 15 years' experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Mr Osagie Imasogie has over 30 years of experience in law, finance, business management, healthcare, and the pharmaceutical industry. He is co-founder and Senior Managing Partner of PIPV Capital, a Private Equity firm focused on the Life Sciences sector. Prior to co-founding PIPV Capital, he conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. He has held senior legal, commercial, and R&D positions at pharmaceutical companies including GSK, SmithKline, DuPont Merck, and Endo, where he was founding General Counsel and Senior Vice President for Corporate Development.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Dr Odumosu was Ilera Healthcare's first Chief Operating Officer, leading the design, implementation, and management of Ilera's business operations following its license award in 2017. He oversaw day-to-day operations of Ilera's vertically integrated grower/processor, wholesale, and dispensary and led the formulation of Ilera's proprietary cannabinoid-based product.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of several products across various therapeutic categories. He has nearly 20 years of experience in healthcare, building a foundation of knowledge across marketing and the commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse career in healthcare, life sciences, and public service focused in the Greater Philadelphia area. She was formerly a principal with O'Donnell Associates, working with clients including non-profit organisations, universities, and life science companies such as Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 9.54% |
| Sunset Capital Management Pty Ltd | 573,725 | 4.82% |
| Securities Vault Pty Ltd | 488,059 | 4.10% |
| Quincy Street Capital Llc | 456,622 | 3.84% |
| Sharri J Rochlin | 393,168 | 3.30% |
| Osagie Imasogie | 393,168 | 3.30% |
| Mr Zoltan Kerekes | 393,168 | 3.30% |
| Ms Lisa Gray | 381,988 | 3.21% |
| BNP Paribas Nominees Pty Ltd | 341,932 | 2.87% |
| Mera I Llc\C | 332,479 | 2.79% |
| Mr Torsten M Geers | 307,454 | 2.58% |
| Mr Steve Shapiro | 302,571 | 2.54% |
| Mara Gordon | 252,242 | 2.12% |
| Mr Saul Shorr Mrs Margaret Shorr | 151,285 | 1.27% |
| Dr Chanda Latrice Macias | 146,479 | 1.23% |
| Mera Ii Llc\C (i) | 133,372 | 1.12% |
| Oludare Odumosu | 131,766 | 1.11% |
| Citicorp Nominees Pty Limited | 121,342 | 1.02% |
| Mr Daniel Hexter Mrs Shannon Hexter | 103,389 | 0.87% |
| Geers Egag Llc | 85,715 | 0.72% |
